XARELTO Media Monitoring – Week of 8-28-15

Plaintiff Attorney Press Releases

1. Xarelto Lawsuit Update: Xarelto Manufacturers Allegedly Concealed Drug's Dangers

   Aug 26, 2015 | The Digital Journal

   By Marc Goldich
   
   
   BloodThinnerHelp.com reports on a new update on Xarelto lawsuits. Recent Xarelto lawsuits allege that the drug's manufacturers concealed information about the drugs dangers from patients and doctors. Xarelto's Advertising Campaigns Mislead Users: Xarelto sales in the past year have totaled to about $1 billion. The intense marketing campaign that Xarelto's manufacturers, Bayer AG and Janssen Pharmaceuticals, have implemented since the drug's release, touting Xarelto as a more convenient alternative to other blood thinners, is responsible for the massive return in sales. What the marketing campaigns fail to mention is the danger that Xarelto carries with it. Xarelto is part of a new group of blood thinners called Xa inhibitors. Xa inhibitors block the chemical in the blood that is responsible for making blood clot, thrombin.
2. Xarelto Lawsuit Update: Clinical Guidelines Warn Those With End-Stage Kidney Disease

   Aug 27, 2015 | Digital Journal

   By Marc Goldich
   
   
   BloodThinnerHelp.com reports on a new development in Xarelto side effects research. Since its release, Xarelto's run on the United States blood thinner market has been plagued with many Xarelto lawsuits alleging that the drug causes serious adverse events including the development of blood clots, pulmonary embolism, and uncontrollable internal bleeding. The FDA has since then attached two 'Black Box' labels to Xarelto, the most strict warning the organization can hand out to a drug.

Plaintiff Attorney Blog Posts

3. Xarelto Lawyer

   Aug 21, 2015 | Tate Law Group

   Pharmaceutical companies have a responsibility to develop prescription drugs that are safe for consumers. The makers of Xarelto, Bayer and Janssen Pharmaceuticals, are defendants in several Xarelto lawsuits because of the alleged deffective and dangerous nature of the drug. If you or a loved one has experienced a severe bleeding occurrence after taking Xarelto, you may be entitled to take legal action with a Xarelto lawyer.
4. Xarelto Dangerous Side Effects

   Aug 21, 2015 | Nager, Romaine & Schneiberg, Co. L.P.A.

   Approved by the FDA in 2011, Xarelto is an anticoagulant blood thinner manufactured by Bayer and marketed in the U.S. by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. Similar to other blood thinners such as Coumadin and Pradaxa, Xarelto is prescribed to reduce the risks of stroke and blood clots in individuals suffering from atrial fibrillation, also known as A-Fib.
5. More Plaintiffs Added To Xarelto MDL, Bellwether Details Released

   Aug 22, 2015 | 24-7 Lawsuit News

   Close to 200 plaintiffs represented in four lawsuits were added to the Xarelto MDL in July, as proceedings in the multidistrict litigation progress more than seven months after certification. The lawsuits allege that the blood thinner Xarelto lacked a reversal agent, leading to major bleeding accidents including a number of deaths. The lawsuits center around allegations that Bayer, the pharmaceutical company and manufacturer of Xarelto, failed to warn consumers of the bleeding risks associated with the drug. The complaints state that not only did Bayer put patients in harm's way by marketing the medication with a heightened risk of serious injuries, but that the company knew of the dangers associated with Xarelto and continued to sell the drug.
6. The MDL: What Does This Mean For Xarelto Lawsuits

   Aug 24, 2015 | The Legal Herald

   By Marc Goldich
   
   
   Recently, many of the federally filed lawsuits have been consolidated into a multidistrict litigation that is based out of the eastern district of Louisiana. Judge Eldon Fallon is presiding over the multidistrict litigation (MDL). He has been working in the Eastern District of Louisiana since May 10, 1995. At this point, more than 400 lawsuits have been transferred to the Louisiana MDL. There is also a mass tort group in Philadelphia, PA where more than 100 lawsuits are currently filed.
7. Xarelto Multidistrict Litigation Adds Plaintiff from Ohio

   Aug 24, 2015 | Top Class Actions

   By Paul Tassin
   
   
   Plaintiff Samuel S. of Ohio has added his Xarelto lawsuit to a multidistrict litigation now going on in federal court in New Orleans. This MDL is a consolidation of several individual Xarelto lawsuits into a single action in a single court. Generally, the plaintiffs in these Xarelto lawsuits blame Xarelto for dangerous episodes of gastrointestinal bleeding and other types of excessive blood loss. They allege the risks involved in Xarelto bleeding are too high for the drug to be considered safe. They also accuse the manufacturers of Xarelto of failing to properly address those risks in their labeling and marketing.
8. Xarelto -- HarmfulDrugAttorneys.com

   Aug 26, 2015 | Leifer Law Firm

   Were you or a loved one injured because of the prescription drug Xarelto? Xarelto was a revolutionary prescription medication of its time. But, as its use become more prominent in the United States, it was apparent that there was something wrong with this medication. This prescription has been linked to hundreds of injuries and deaths since its approval in 2011. And, there have already been over 80 lawsuits filed with claims of injury, permanent disability and death all related to taking this medication.
9. Janssen Hit With Another Xarelto Lawsuit For Internal Bleeding

   Aug 26, 2015 | Top Class Actions

   By Tamara Burns
   
   
   Another dangerous drug lawsuit has been brought against Janssen Pharmaceuticals for personal injury resulting from the use of Xarelto, an anticoagulant drug. Plaintiff Andrew S., a resident of New Hampshire, was prescribed Xarelto from his physician on Sept. 7, 2014 to treat his atrial fibrillation and began taking it the next day. He discontinued Xarelto only one week after he began using it on Sept. 15. According to the Xarelto lawsuit, he began to develop bloody stools, and his doctor ordered him to collect stool samples to be analyzed on that same day. A few days later, Andrew’s condition worsened and he was admitted to the hospital for internal bleeding, severe weakness and low hematocrit levels in the blood.
10. Xarelto Lawsuit

    Aug 26, 2015 | Baron Budd

    Drugs used as blood thinners are supposed to help prevent serious health problems, not cause them. Lawyers at Baron & Budd are currently investigating problems with the blood thinner Xarelto. Xarelto can significantly increase the risk of internal bleeding and even cause other dangerous health problems, such as kidney failure, liver damage, blood clots, internal bleeding (including hemorrhage, hematoma or other bleeding problems), stroke or even death.
11. Xarelto Lawsuits Are Still Moving Forward

    Aug 26, 2015 | The Levensten Law Firm

    By Scott Levensten
    
    
    Federally filed Xarelto lawsuits have been centralized in the U.S. District Court in Louisiana. Centralizing the cases for the pre-trial proceedings has benefits including: consolidating the cases promotes efficiency, consolidating the cases lowers the risks of duplication, consolidating the cases lowers the chances of inconsistent rulings, and all Xarelto lawsuits will have similar findings because of the similar claims.
12. Teen Dies After 3 months of Xarelto Use

    Aug 27, 2015 | Texas Injury Law Blog

    By Majed Nachawati
    
    
    Sean David Pulskamp died tragically after taking Xarelto for three months. The cause of death was listed as cardiopulmonary arrest, pulmonary embolism, deep vein thrombosis, and pulmonary hypertension. Mr. Pulskamp was only 19 years old. Growing concerns over deaths and complications from blood thinners like Xarelto are forcing leading cardiologists to reconsider prescribing them. These risks and trends should not be ignored. Patients nationwide are reporting serious life-threatening issues after taking Xarelto, such as uncontrolled internal bleeding, hemorrhaging, stroke and/or death.
13. Xarelto Is Unsafe Because of Bleeding Risks -- And There is No Antidote

    Aug 27, 2015 | The Levensten Law Firm

    By Scott Levensten
    
    
    Manufactured in the United States by Bayer and marketed by Janssen Pharmaceuticals, Xarelto (Rivaroxaban) is currently prescribed by physicians to their patients as an anti-coagulant. First introduced in 2011, the primary target of Xarelto was blood clots in knee and hip replacement patients. Secondarily it is being promoted as a way to prevent blood clots attributed to atrial fibrillation.
14. Xarelto Lawyers Can They Protect You? (YouTube Video)

    Aug 27, 2015 | YouTube

    By Meldofsky Firm LLC
    
    
    Need help with Xarelto lawsuit? Contact www.xareltoinjurylawsuits.info now! Address: 23615 El Toro Road Suite X329 Lake Forest, CA 92630 Phone: 877-274-8672
15. Xarelto Bleeding Lawsuit Joins MDL Alleging Wrongful Death

    Aug 28, 2015 | Top Class Actions

    By Melissa LaFreniere
    
    
    A Louisiana family joined the growing Xarelto bleeding multidistrict litigation after losing their loved one to a cerebral bleeding event blamed on the drug. According to plantiff Aquantae C., who filed the Xarelto lawsuit on behalf herself and the estate of Regina N., Regina began taking Xarelto in January 2014 and as a direct result suffered from internal bleeding and a mini-stroke in August 2014. The family claims Regina died the following month due to the injuries she sustained from the Xarelto bleeding side effects.

Plaintiff Attorney Press Releases

1. Xarelto Lawsuit Update: Xarelto Manufacturers Allegedly Concealed Drug's Dangers

   Aug 26, 2015 | The Digital Journal

   By Marc Goldich

   BloodThinnerHelp.com reports on a new update on Xarelto lawsuits.  Recent Xarelto lawsuits allege that the drug's manufacturers concealed information about the drugs dangers from patients and doctors.

   Xarelto's Advertising Campaigns Mislead Users:

   Xarelto sales in the past year have totaled to about $1 billion.  The intense marketing campaign that Xarelto's manufacturers, Bayer AG and Janssen Pharmaceuticals, have implemented since the drug's release, touting Xarelto as a more convenient alternative to other blood thinners, is responsible for the massive return in sales.  What the marketing campaigns fail to mention is the danger that Xarelto carries with it. Xarelto is part of a new group of blood thinners called Xa inhibitors.  Xa inhibitors block the chemical in the blood that is responsible for making  blood clot, thrombin.  

   The problem with Xarelto is that there is no antidote to the medication.  If a patient suffers an internal bleeding injury, there is no way to stop the bleeding.  With other blood thinners, such as Warfarin, doctors can administer vitamin K to help the blood clot, or in more dire situations emergency dialysis can remove the drug from the system, which was the case with Xarelto's rival, Pradaxa.  Neither of these methods will work if the patient is taking Xarelto, which can lead to serious injuries. 

   Xarelto Lawsuits Allege Bayer Knew of Drug Dangers:

   Recent Xarelto lawsuits allege that Bayer knew of the dangers that Xarelto carried and purposely failed to mention it in the drug's warning labels.
   Bayer's defense against these lawsuits is based on two studies.  One of the studies in question was sponsored by Bayer and the other by Janssen, the other company involved in Xarelto lawsuits. 

   The first study completed was published on September 8, 2011 in the New England Journal of Medicine.  The study was called "Rocket-AF", AF being the condition 'atrial fibrillation'.  The study compared rivaroxaban (the active ingredient in Xarelto) to warfarin in regards to their effectiveness of stroke prevention and how they worked to treat AF.  This particular study concluded that there were “no significant differences in rates of major and clinically relevant nonmajor bleeding" between the patients who were treated with warfarin and the patients who received rivaroxaban.

   The second study to be published that is part of Bayer's defense is a comparison between Xarelto and another type of anticoagulant, enoxaparin sodium, a 'low-molecular weight heparin'.  This study is known as "Einstein PE", the PE referring to pulmonary embolism, and concluded that Xarelto only had a small "superiority for major bleeding" when compared to the other blood thinner."

   Both of these studies failed to discuss the drug's lack of a reversal agent.
   "If Bayer knew about this information, it is unacceptable for them to deliberately withhold it from patients and doctors." said Marc Goldich, an experienced attorney working on Xarelto lawsuits, "We will help victims seek justice in court."

   For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

   http://www.digitaljournal.com/pr/2657117
   

   Return to headline | Return to top

2. Xarelto Lawsuit Update: Clinical Guidelines Warn Those With End-Stage Kidney Disease

   Aug 27, 2015 | Digital Journal

   By Marc Goldich

   BloodThinnerHelp.com reports on a new development in Xarelto side effects research.  Since its release, Xarelto's run on the United States blood thinner market has been plagued with many Xarelto lawsuits alleging that the drug causes serious adverse events including the development of blood clots, pulmonary embolism, and uncontrollable internal bleeding.  The FDA has since then attached two 'Black Box' labels to Xarelto, the most strict warning the organization can hand out to a drug.
   

   Recently, new clinical guidelines have been released in which doctors warn that patients with serious kidney problems should not be taking Xarelto due to the risk of blood clots, stroke, and excess bleeding.

   Patients With Kidney Disease Advised to Avoid Xarelto Due To Side Effects:

   Established medical groups such as The American College of Cardiology, The American Heart Association, and the Society of Thoracic Surgeons have all worked together to develop treatment guidelines for patients who need to be medicated with blood thinning drugs.

   These groups collectively advised that when patients are diagnosed with chronic kidney disease (CKD), "warfarin should be used".  They stressed that warfarin be used in cases where the patient is receiving hemodialysis or those who are in serious stages of kidney failure.  While they noted that blood thinners such as Xarelto, rivaroxaban, may be considered for use in patients with moderate to severe CKD, they said that these drugs should not be used in patients with end-stage CKD.

   The use of blood thinners in patients with CKD requires doctors to be careful because these patients are at a higher risk of experiencing blood clots and have a higher risk of bleeding complications.  This is problematic with Xarelto because when the kidney's aren't functioning correctly, they are not capable of processing drugs normally and flushing them totally out of the system.  This can potentially result in too much of the drug being in the body at once, therefore increasing the risk even further for an internal bleeding event.   For these reasons, Xarelto is not recommended to use with patients who are in stage 5 CKD.

   Lack of Antidote Makes Xarelto Side Effects More Dangerous:

   When Xarelto was released onto the market in 2011, the manufacturers of the drug, Bayer AG and Johnson&Johnson's pharmaceutical unit, Jannsen Pharmaceuticals, advertised the drug as an easier alternative to warfarin, with its 'one size fits all' method of dosing and the relaxed blood testing and dietary restrictions required for the drug's success.  However, what the manufacturers failed to warn doctors and patients of is the fact that unlike warfarin, Xarelto does not have an antidote to reverse its effects.  Because there is no antidote, if a patient taking Xarelto suffers from an internal bleeding event, there is no way to stop the bleeding, leading to an uncontrollable bleeding event and serious injury.

   A study completed in 2015 revealed that blood monitoring in patients taking Xarelto would have been very helpful in assessing a patient's risk for excessive bleeding, despite the manufacturer's endless claims that this step was not necessary.

   For more information about the Xarelto litigation, please direct all inquiries to Marc Goldich via 866-425-8902.

   http://www.digitaljournal.com/pr/2655851
   

   Return to headline | Return to top

Plaintiff Attorney Blog Posts

3. Xarelto Lawyer

   Aug 21, 2015 | Tate Law Group

   Pharmaceutical companies have a responsibility to develop prescription drugs that are safe for consumers. The makers of Xarelto, Bayer and Janssen Pharmaceuticals, are defendants in several Xarelto lawsuits because of the alleged deffective and dangerous nature of the drug. If you or a loved one has experienced a severe bleeding occurrence after taking Xarelto, you may be entitled to take legal action with a Xarelto lawyer.

   Xarelto was introduced in the United States market in July of 2011, and is part of a class of drugs called New Oral Anticoagulants (NOACs). This class of NOACs, which also includes Pradaxa and Eliquis, has been marketed as the next generation of blood-thinning drugs and has been prescribed to prevent pulmonary embolism and deep vein thrombosis, as well as strokes in patients suffering from atrial fibrillation, and for patients who had undergone knee and hip replacement procedures. The manufacturing company, Bayer and Janssen Pharmaceuticals – a division of Johnson & Johnson – reported that approximately 130,000 prescriptions were written for Xarelto in the first three months of 2012 in the U.S. alone.

   However, Xarelto carries a significant risk of severe, and sometimes even fatal, internal bleeding – and there is no reversal agent available if serious bleeding occurs with Xarelto use. In 2013, the Institute for Safe Medication Practices (ISMP) announced that the U.S. Food and Drug Administration (FDA) reported receiving 680 serious adverse event reports from individuals who alleged to have suffered adverse events while taking Xarelto. That number quickly rose to more than 1,800 adverse events linked to Xarelto, the most common events were pulmonary embolism, deep vein thrombosis, gastrointestinal hemorrhage, and hemorrhage. Hospitalization was reported in 891 of these events; 183 patients lost their lives.

   As a result of many adverse event reports, the FDA required the makers of Xarelto to issue ‘black box’ warnings about the potential hazards of using Xarelto. The ‘black box’ warning is the most urgent type of warning that is issued by the FDA. This warning advised that Xarelto print advertisement was “false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim” regarding blood monitoring and “no dosage adjustments.” To date, more than 21,000 adverse events have been linked to Xarelto.

   Xarelto Side Effects

   The reason Xarelto is so much more dangerous than other anticoagulants on the market, is that it causes uncontrollable bleeding that cannot be reversed. Other blood thinners can be controlled with Vitamin K, but Xarelto does not respond to Vitamin K. There is no antidote for excessive bleeding caused by taking Xarelto, leaving patients at a much greater risk of bleeding to death.

   Commonly reported side effects of Xarelto include:

   Back pain

   Bleeding gums

   Bloody stools

   Prolonged bleeding from cuts

   Nose bleeds

   Bloody coughs

   Xarelto Lawsuit

   Several plaintiffs have filed lawsuits against the makers of Xarelto. They allege the drug caused cerebral hemorrhaging, gastrointestinal bleeding and fatalities. Due to the severe blood thinning effects of Xarelto, plaintiffs further claim:

   The makers of Xarelto continued to market the drug as being safe after they found out it was not

   The makers of Xarelto did not give doctors actions to take to assist patients who experienced excessive bleeding as a result of taking Xarelto

   The makers of Xarelto are motivated by profits more than maintaining the safety of Xarelto

   Consumers were not warned by the makers of Xarelto about the dangers associated with taking the drug

   Pharmaceutical companies must be held accountable for any action that causes harm and loss to consumers. It is the right of any Xarelto user who has been harmed to file a Xarelto lawsuit against the companies Bayer and Janssen Pharmaceuticals. If you or a loved one have suffered as a result of taking Xarelto, you may be eligible to be compensated for pain, suffering, past/future medical bills, and funeral expenses.Filing a Xarelto lawsuit does not take away the pain you have suffered, but it can ease your financial and emotional burdens. If you have been harmed by Xarelto, you may be able to receive compensation. Contact an experienced Xarelto lawyer today.

   If you or a loved one suffered serious injury after using Xarelto, please contact the attorneys at the Tate Law Group toll free at (866)610-7101 for your confidential and free consultation.

   http://tatelawgroup.com/prescription-drugs-medical-devices/xarelto-lawyer/
   

   Return to headline | Return to top

4. Xarelto Dangerous Side Effects

   Aug 21, 2015 | Nager, Romaine & Schneiberg, Co. L.P.A.

   Have you or a family member been affected by the adverse effects of Xarelto? Then you may want to learn more about dangerous side effects and the potential for filing a lawsuit.  

   Background

   Approved by the FDA in 2011, Xarelto is an anticoagulant blood thinner manufactured by Bayer and marketed in the U.S. by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. Similar to other blood thinners such as Coumadin and Pradaxa, Xarelto is prescribed to reduce the risks of stroke and blood clots in individuals suffering from atrial fibrillation, also known as A-Fib.

   Bleeding Side Effects

   Unfortunately, Xarelto can also cause uncontrollable bleeding. The drug does not have an antidote and those filing lawsuits after being injured by the drug say they were not sufficiently warned before taking Xarelto. The first complaints were filed in early 2014, and by mid-2015 the number of claims involved in the Xarelto litigation has already reached 2,000.

   Last May, a suit was filed in Pennsylvania on behalf of a woman who died after taking Xarelto. The Xarelto bleeding lawsuit states that Bayer and Janssen Pharmaceuticals, “fervently marketed” Xarelto without regard for reports of 356 serious, disabling and fatal injuries involving major bleeding, hemorrhaging and death. A Florida woman also filed suit after her husband died after taking Xarelto to treat A-Fib. Further, the drug is suspected of causing 72 deaths in the first quarter of 2013 in Germany alone.

   FDA Issues Serious Warnings

   The FDA has issued two block box (the strictest) warnings on Xarelto:

   People with A-Fib, not caused by a heart valve problem, who discontinue Xarelto without replacing it with another blood thinner are at risk for dangerous blood clots

   A spinal anesthesia performed on a person taking Xarelto may result in bleeding around the spine that can lead to long-term or permanent paralysis.

   No-Cost Evaluation

   The Xarelto attorneys at Nager, Romaine & Schneiberg are here to advocate on your behalf. If you or a loved one has experienced life-threatening and related side effects following the use of Xarelto, you may be entitled to compensation. These may include:

   Stroke

   Heart attack

   Gastrointestinal bleeding

   Hemorrhaging

   Blood Clots

   Death

   The Xarelto lawyers at NRS will evaluate the feasibility of a lawsuit and help determine whether you are entitled to compensation. Call NRS at 216-289-4740, or toll-free form Ohio at (855) GOT-HURT. You can alsofill out our contact form for a free consultation.

   http://www.nrsinjurylaw.com/blog/view/xarelto-dangerous-side-effects
   

   Return to headline | Return to top

5. More Plaintiffs Added To Xarelto MDL, Bellwether Details Released

   Aug 22, 2015 | 24-7 Lawsuit News

   Close to 200 plaintiffs represented in four lawsuits were added to the Xarelto MDL in July, as proceedings in the multidistrict litigation progress more than seven months after certification. The lawsuits allege that the blood thinner Xarelto lacked a reversal agent, leading to major bleeding accidents including a number of deaths.

   The lawsuits center around allegations that Bayer, the pharmaceutical company and manufacturer of Xarelto, failed to warn consumers of the bleeding risks associated with the drug. The complaints state that not only did Bayer put patients in harm's way by marketing the medication with a heightened risk of serious injuries, but that the company knew of the dangers associated with Xarelto and continued to sell the drug.

   Xarelto was initially designed to offer an alternative to the long-time blood thinning medication Warfarin, which had been a top choice among physicians for decades. Both medications are prescribed to help battle deep vein thrombosis, a condition that can lead to strokes and other serious complications that can be relieved by thinning a patient's blood. Xarelto was hailed as a step forward in blood thinning medication, and became popular as its use around the country grew. However, Xarelto lacked a reverse agent, an important element of Warfarin that helped clot blood in the event that a bleeding incident might occur.

   The reverse agent in Warfarin was Vitamin K, which was not employed in the design of Xarelto. As a result, when a patient taking Xarelto began to bleed their thinned blood would have no way to clot and stop the flow from a wound. The number of serious bleeding incidents reported that were related to Xarelto begin to grow as the lack of a reverse agent resulted in a rash of bleeding incidents caused by the drug, which topped out at $2 billion in sales in 2013. At least 65 deaths have been allegedly connected to Xarelto's lack of a reverse agent.

   More than 1,200 lawsuits have been filed thus far against Bayer in connection with Xarelto, with most of them being consolidated in the multidistrict litigation that is pending before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana federal court. A similar blood thinning drug that came out around the same time, Pradaxa, is also dealing with a large amount of lawsuits alleging similar claims to those filed against Bayer over Xarleto.

   Recent Xarelto research has also added to the evidence that will likely be presented by the plaintiffs, as the medical journal Circulation published a report in July claiming that neither Xarelto or its main competitor Pradaxa were any more effective than Warfarin as blood thinners. The research tested the efficacy and safety of the drugs and compared the results, which revealed that although the newer drugs were hailed as safer and more effective by the manufacturers, those claims were likely to have been false.

   The first set of bellwether trials in the Xarelto MDL are expected to begin in August of 2016. The trials will take place in the Eastern District of Louisiana, Southern District of Texas and Southern District of Mississippi federal courts.

   http://www.247lawsuitnews.com/news/more-plaintiffs-added-to-xarelto-mdl-bellwether.asp
   

   Return to headline | Return to top

6. The MDL: What Does This Mean For Xarelto Lawsuits

   Aug 24, 2015 | The Legal Herald

   By Marc Goldich

   Recently, many of the federally filed lawsuits have been consolidated into a multidistrict litigation that is based out of the eastern district of Louisiana. Judge Eldon Fallon is presiding over the multidistrict litigation (MDL). He has been working in the Eastern District of Louisiana since May 10, 1995.

   At this point, more than 400 lawsuits have been transferred to the Louisiana MDL. There is also a mass tort group in Philadelphia, PA where more than 100 lawsuits are currently filed.

   Xarelto Lawsuits Filed in Multidistrict Litigation

   Individuals who suffered from an injury as a result of taking Xarelto have been filing lawsuits against the drug. These individuals have experienced injuries such as excessive blood clots or severe internal bleeding. Because of the severe injuries that Xarelto allegedly causes, there have been many instances where patients who took Xarelto die as a result of the serious side effects. The estate and family of the deceased have the right to file a wrongful death lawsuit against the manufacturers of Xarelto.

   Although they often get mixed up, an MDL is very different from a class action lawsuit. There is currently no class action lawsuit filed against Bayer AG or Johnson&Johnson concerning Xarelto and internal bleeding. Because of the severity of the injuries that Xarelto is alleged to cause and the variety of injuries among the cases, a class action lawsuit is not appropriate for this type of legal action, since a class action lawsuit means that the verdict will be the same for every party involved. An MDL allows for each case to be heard individually and verdicts to be decided on a case to case basis.

   A multidistrict litigation requires that all of the lawsuits filed in it make similar allegations against Xarelto’s manufacturers. Most lawsuits filed allege that Xarelto caused uncontrollable internal bleeding which resulted in serious injury of the plaintiff or the death of a loved one.

   What Will a Xarelto Lawsuit Settle for?

   While it is too early to predict what the Xarelto lawsuits will settle for, previous lawsuits may give us an idea. In May 2014, there were lawsuits brought against a blood thinner similar to Xarelto, Pradaxa. Their manufacturers, Boehringer Ingelheim, settled 4,000 lawsuits concerning Pradaxa for $650 million.

   “When one takes into consideration the incidence of internal bleeding among Xarelto users, we can expect that thousands of lawsuits will eventually be filed,” experienced Xarelto attorney Marc Goldich said.

   For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

   http://legalherald.com/the-mdl-what-does-this-mean-for-xarelto-lawsuits/
   

   Return to headline | Return to top

7. Xarelto Multidistrict Litigation Adds Plaintiff from Ohio

   Aug 24, 2015 | Top Class Actions

   By Paul Tassin

   Plaintiff Samuel S. of Ohio has added his Xarelto lawsuit to a multidistrict litigation now going on in federal court in New Orleans.

   This MDL is a consolidation of several individualXarelto lawsuits into a single action in a single court. Generally, the plaintiffs in these Xarelto lawsuits blame Xarelto for dangerous episodes of gastrointestinal bleeding and other types of excessive blood loss. They allege the risks involved in Xarelto bleeding are too high for the drug to be considered safe. They also accuse the manufacturers of Xarelto of failing to properly address those risks in their labeling and marketing.

   Defendants in the Xarelto MDL are Janssen, its parent company Johnson & Johnson, Bayer Healthcare Pharmaceuticals Inc. and their related companies.

   Xarelto Bleeding

   Xarelto, or rivaroxaban, is an anticoagulant medication that is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation; to treat deep vein thrombosis and pulmonary embolism, and to prevent their recurrence; and to prevent deep vein thrombosis in patients following hip or knee replacement surgery.

   Xarelto is one of a new class of anticoagulants that recently entered the market. Prior to then, warfarin (also sold under the brand name Coumadin) had been the go-to anticoagulant medication for most patients since the 1950s.

   Warfarin does come with the disadvantages of requiring dietary restrictions and ongoing monitoring of blood levels. Janssen’s marketing for Xarelto says it does not impose the same requirements on patients, plaintiffs allege.

   However, as with the other new anticoagulants, there is no other medication that can control Xarelto bleeding once it starts. Excessive bleeding caused by warfarin can be resolved by administering vitamin K. Plaintiffs argue that Janssen’s labeling for Xarelto should have disclosed this fact in the “Warnings” section.

   The joint complaint for the Xarelto MDL cites criticism by the FDA of the clinical studies used during Xarelto’s FDA approval process. Inspection during an earlier set of studies known as the RECORD studies allegedly revealed “’systemic discarding of medical records,’ unauthorized unblinding, falsification, and ‘concerns regarding improprieties in randomization.’” Plaintiffs report that based on these findings, the FDA deemed the RECORD 4 studies unreliable.

   Similar FDA findings cast suspicion on a later set of studies known as the ROCKET-AF studies. These studies were conducted to compare Xarelto to warfarin as a preventive for stroke and systemic embolism in patients with non-valvular atrial fibrillation. The FDA found, however, that the researchers’ control of the warfarin group was poor enough to make the resulting data inadequate to determine Xarelto’s effectiveness as compared to warfarin.

   The FDA also questioned the ROCKET-AF researchers’ study of only once-daily Xarelto dosing. The agency noted that certain clinical information suggested that twice-daily dosing would result in lower peak blood levels and might therefore result in greater efficacy and possibly more safety. An FDA doctor expressed concern that the once-daily dosage was selected more for marketing advantage than for scientific reasons.

   The Xarelto Lawsuit is Case No. 2:15-CV-2210, in the U.S. District Court for the Eastern District of Louisiana.

   http://topclassactions.com/lawsuit-settlements/lawsuit-news/98812-xarelto-multidistrict-litigation-adds-plaintiff-ohio/
   

   Return to headline | Return to top

8. Xarelto -- HarmfulDrugAttorneys.com

   Aug 26, 2015 | Leifer Law Firm

   Were you or a loved one injured because of the prescription drug Xarelto?

   Xarelto was a revolutionary prescription medication of its time. But, as its use become more prominent in the United States, it was apparent that there was something wrong with this medication. This prescription has been linked to hundreds of injuries and deaths since its approval in 2011. And, there have already been over 80 lawsuits filed with claims of injury, permanent disability and death all related to taking this medication.

   Why File a Lawsuit Against Xarelto?

   This drug is one of the newer blood thinning medications on the market. It was manufactured by Bayer and marketed by the company Johnson & Johnson through their subsidiary Janssen Pharmaceuticals. The most dangerous side effect of this drug is severe, uncontrollable bleeding. Doctors from around the country are worried about this side effect, and there have already been numerous deaths and injuries associated with this drug.

   If you do not think you have a case, here are a few reasons to reconsider:

   You have had financial hardship; therefore, you deserve financial compensation. You may have ongoing medical costs, lost wages or even long-term disability costs to deal with.

   The emotional stress of caring for someone who has been injured because of this drug or losing a loved one to severe bleeding should not go unnoticed.

   You may have encountered burial costs for the loss of a loved one who died because of Xarelto.

   You need to hold the manufacturer and marketing companies responsible for releasing a drug they knew could cause serious harm or death.

   Contact the Xarelto Advocates at Leifer Law Firm Today

   Whether you need to file an injury case or wrongful death suit, do not join the class action lawsuits. Instead, hire your own attorney to make sure you get the compensation you deserve based on your case instead of splitting equally with everyone. The company should have concealed these dangerous risks or researched their drug long enough to find these risks before releasing it to the public.

   Because the company didn’t perform their duty of care, you should hold them responsible for your losses.

   Whether you or a loved one suffered from severe bleeding, blood clots or other dangerous side effects, you have a right to compensation.

   Contact the Leifer Law Firm team today at 855-534-3375 for a free consultation.

   http://harmfuldrugattorneys.com/xarelto/
   

   Return to headline | Return to top

9. Janssen Hit With Another Xarelto Lawsuit For Internal Bleeding

   Aug 26, 2015 | Top Class Actions

   By Tamara Burns

   Another dangerous drug lawsuit has been brought against Janssen Pharmaceuticals for personal injury resulting from the use of Xarelto, an anticoagulant drug.

   Plaintiff Andrew S., a resident of New Hampshire, was prescribed Xarelto from his physician on Sept. 7, 2014 to treat his atrial fibrillation and began taking it the next day. He discontinued Xarelto only one week after he began using it on Sept. 15. According to the Xarelto lawsuit, he began to develop bloody stools, and his doctor ordered him to collect stool samples to be analyzed on that same day. A few days later, Andrew’s condition worsened and he was admitted to the hospital for internal bleeding, severe weakness and low hematocrit levels in the blood.

   After being sent to a gastroenterologist, it was determined that Andrew had a serious internal bleed originating from the portal connection the esophagus to the stomach. He still suffers from this issue that is potentially life-threatening, and is currently undergoing treatment.

   In this Xarelto lawsuit, nine counts have been brought against the drug manufacturer. These include negligence in product testing and manufacture, warnings provided, strict products liability, breach of express and implied warranties, fraudulent misrepresentation and omission, negligent misrepresentation, fraud and deceit, and violation of the New Hampshire Consumer Protection Act.

   Andrew is seeking compensatory, consequential, and punitive damages with respect to past, present and future medical expenses, attorney and related fees, and for other extraordinary, declaratory or injunctive relief as permitted by law to ensure an effective remedy for his gastrointestinal bleeding.

   Andrew’s situation is just one of many Xarelto lawsuits against Janssen Pharmaceuticals which all similarly allege serious complications following use of the blood thinner. According to this plaintiff, he had only taken the medication for a week and suffered major internal bleeding damage that could potentially last a lifetime.

   Xarelto Uses and Internal Bleeding

   Xarelto (rivaroxaban) is a newer generation anticoagulant medication used to reduce stroke risk from atrial fibrillation (Afib), deep vein thrombosis (DVT) and pulmonary embolism (PE) and also to treat DVT and PE. Prior to the newer anticoagulant drugs (Xarelto, Pradaxa and Eliquis), warfarin was the most commonly used anticoagulant that was generally deemed safe.

   While bleeding complications are a known as the most common side effect of all classes of anticoagulants, warfarin is the only drug that has an antidote to the bleeding. Fresh frozen plasma along with intravenous Vitamin K are the most commonly used interventions to restore bleeding to normal and gain control of any bleeding events. None of the new generation of anticoagulants has an antidote, allowing the internal bleeding to persist indefinitely without a timely solution.

   Over the last few years, the number of reports to the FDA for Xarelto bleeding have increased. In 2012, there were 1218 cases filed, the number tripled in 2013 to 3600 cases, and through October of 2014, there were 3011 cases filed with the FDA.

   Xarelto Lawsuit Information

   If you or someone you love has experienced internal bleeding after taking Xarelto, you may be entitled to legal damage for your Xarelto injury, pain and suffering. A Xarelto lawyer can provide a free consultation to individually discuss your confidential situation.

   The Xarelto Bleeding Lawsuit is Case No. 1:15-cv-00022, in the U.S. District Court for the District of New Hampshire.

   http://topclassactions.com/lawsuit-settlements/lawsuit-news/97857-janssen-hit-another-xarelto-lawsuit-internal-bleeding/
   

   Return to headline | Return to top

10. Xarelto Lawsuit

    Aug 26, 2015 | Baron Budd

    Drugs used as blood thinners are supposed to help prevent serious health problems, not cause them. Lawyers at Baron & Budd are currently investigating problems with the blood thinner Xarelto.

    Xarelto can significantly increase the risk of internal bleeding and even cause other dangerous health problems, such as kidney failure, liver damage, blood clots, internal bleeding (including hemorrhage, hematoma or other bleeding problems), stroke or even death.

    To see if you have a Xarelto lawsuit, contact a Xarelto lawyer at 1.866.795.8339 or contact us online to see if you qualify.

    Why File a Xarelto Lawsuit?

    A Xarelto lawsuit is one of the very few ways that you can stand up against the pharmaceutical companies and hold them accountable. By filing a Xarelto lawsuit, you can recover money to help cover expensive medical costs or make up for lost income because of health problems related to Xarelto use.

    What Is Xarelto?

    As a heavily marketed blood thinner approved in 2011, Xarelto quickly became a billion-dollar drug. Xarelto is supposed to prevent blood clots and treat existing blood clots and thus help protect patients from having strokes. Unfortunately, the blood thinner may also cause uncontrolled internal bleeding that is so severe that it can lead to hospitalization or even death.

    What’s So Dangerous About Xarelto?

    All blood thinners have a risk of excessive bleeding, such as internal bleeding. To help manage the risks associated with excessive bleeding, especially in emergency situations, most blood thinners are capable of being reversed. When the need arises to stop or prevent fatal hemorrhaging, medical professionals will administer vitamin K or fresh frozen plasma as soon as possible. These agents act to thicken the blood, preventing fatal bleeding events. It can be referred to as an antidote.

    Xarelto CANNOT be reversed. We repeat: There is no known antidote for Xarelto. For patients taking Xarelto who experience internal bleeding or other emergency bleeding events, there is no emergency treatment available to stop the bleeding. In fact, Xarelto cannot even be flushed out of the system through dialysis!

    Patients taking Xarelto may have a particular risk of very serious internal bleeding or excessive bleeding; bleeding that can lead to long stays in the hospital or even death.

    Side Effects of Xarelto May Include:

    Internal bleeding

    Long-lasting or severe external bleeding

    Kidney failure

    Liver damage or other liver problems

    Blood clots

    Brain hemorrhage

    Intracranial Hemorrhage

    Epidural Hematoma

    Gastrointestinal Hemmorrhage

    Retinal Hemorrhage

    Adrenal Bleeding

    Stroke

    DeathSo How Did Xarelto Get to be Such a Big Seller?

    Xarelto is manufactured by the big pharmaceutical company Bayer and marketed by a Johnson & Johnson subsidiary, Janssen Pharmaceuticals. These are two international multi-billion dollar corporations that know how to educate the public and the doctors and medical professionals who prescribe medication.

    http://baronandbudd.com/health/pharmaceuticals/xarelto-blood-thinner-lawsuit/
    

    Return to headline | Return to top

11. Xarelto Lawsuits Are Still Moving Forward

    Aug 26, 2015 | The Levensten Law Firm

    By Scott Levensten

    Federally filed Xarelto lawsuits have been centralized in the U.S. District Court in Louisiana.

    Centralizing the cases for the pre-trial proceedings has benefits including:

    Consolidating the cases promotes efficiency

    Consolidating the cases lowers the risks of duplication

    Consolidating the cases lowers the chances of inconsistent rulings

    All Xarelto lawsuits will have similar findings because of the similar claims

    Further, Xarelto lawsuits that were filed in Pennsylvania have been consolidated in the Philadelphia Court of Common Pleas in a mass tort litigation program for the Xarelto lawsuit.

    If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.

    http://levenstenlawfirm.com/xarelto-lawsuits-are-still-moving-forward/
    

    Return to headline | Return to top

12. Teen Dies After 3 months of Xarelto Use

    Aug 27, 2015 | Texas Injury Law Blog

    By Majed Nachawati

    MISSION HILLS, CA - Sean David Pulskamp died tragically after taking Xarelto for three months. The cause of death was listed as cardiopulmonary arrest, pulmonary embolism, deep vein thrombosis, and pulmonary hypertension. Mr. Pulskamp was only 19 years old.

    Growing concerns over deaths and complications from blood thinners like Xarelto are forcing leading cardiologists to reconsider prescribing them. These risks and trends should not be ignored. Patients nationwide are reporting serious life-threatening issues after taking Xarelto, such as uncontrolled internal bleeding, hemorrhaging, stroke and/or death.

    Legal Commentary
    Fears Nachawati's Xarelto attorneys are studying, examining and investigating Xarelto claims on behalf of people and their families who may have been injured by the drug. Although no monetary amount can compensate for the loss of a loved one, a successful claim against the responsible parties will enable the victim’s family to cover any medical or final expenses, so that they may focus on the grieving process during this trying time. If you or a loved one experienced any side effects while taking Xarelto, contact our Xarelto lawyers to discuss the facts of your potential case. We are available by phone for a free consultation at +1.866.813.1662 or by email at mn@fnlawfirm.com.

    http://www.txinjuryblog.com/2015/08/articles/dangerous-drugs/teen-dies-after-3-months-of-xarelto-use/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+TexasInjuryLawBlog+(Texas+Injury+Law+Blog)
    

    Return to headline | Return to top

13. Xarelto Is Unsafe Because of Bleeding Risks -- And There is No Antidote

    Aug 27, 2015 | The Levensten Law Firm

    By Scott Levensten

    Manufactured in the United States by Bayer and marketed by Janssen Pharmaceuticals, Xarelto (Rivaroxaban) is currently prescribed by physicians to their patients as an anti-coagulant.  First introduced in 2011, the primary target of Xarelto was blood clots in knee and hip replacement patients.  Secondarily it is being promoted as a way to prevent blood clots attributed to atrial fibrillation.

    Unfortunately, a potential side effect of anti-coagulants is bleeding.  Uncontrolled bleeding can be fatal. What sets Xarelto apart from the long time drugs like Coumadin, which uses Vitamin K as an antidote for bleeding, is that with Xarelto there isNO ANTIDOTE.

    A 2012 article in The Huffington Post detailed specific concerns by top heart specialists relating to the use of Xarelto.  Despite those concerns and the ever rising number of injuries and deaths associated with Xarelto it is still on the market.  It is one of the rare drugs that has serious and fatal side effects, and yet has no known antidote.

    The first bellwether trial is scheduled to begin in Louisiana in 2016.

    If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.

    http://levenstenlawfirm.com/xarelto-is-unsafe-because-of-bleeding-risks-and-there-is-no-antidote/
    

    Return to headline | Return to top

14. Xarelto Lawyers Can They Protect You? (YouTube Video)

    Aug 27, 2015 | YouTube

    By Meldofsky Firm LLC

    Need help with Xarelto lawsuit? Contact www.xareltoinjurylawsuits.info now! Address: 23615 El Toro Road Suite X329 Lake Forest, CA 92630 Phone: 877-274-8672

    https://www.youtube.com/watch?v=o7qplMaFsvE
    

    Return to headline | Return to top

15. Xarelto Bleeding Lawsuit Joins MDL Alleging Wrongful Death

    Aug 28, 2015 | Top Class Actions

    By Melissa LaFreniere

    A Louisiana family joined the growing Xarelto bleeding multidistrict litigation after losing their loved one to a cerebral bleeding event blamed on the drug.

    According to plantiff Aquantae C., who filed the Xarelto lawsuit on behalf herself and the estate of Regina N., Regina began taking Xarelto in January 2014 and as a direct result suffered from internal bleeding and a mini-stroke in August 2014. The family claims Regina died the following month due to the injuries she sustained from theXarelto bleeding side effects.

    The family filed the Xarelto wrongful death lawsuit against Janssen Pharmaceuticals, Inc., Johnson & Johnson, and Bayer Healthcare Pharmaceuticals, Inc.

    The family alleges that the manufacturers of Xarelto failed to warn patients that they could risk their lives by taking the medication. The lawsuit claims the defendants’ conduct was “extreme and outrageous” for allegedly intentionally concealing safety concerns from the public.

    According to the Xarelto bleeding lawsuit the “defendants made conscious decisions not to redesign, re-label, warn or inform the unsuspecting consuming public.”

    The plaintiff believes that the conduct of the manufacturers deserves an award of punitive damages.

    The Estate of Regina N. is seeking more than $75,000 to help pay for the medical and nursing treatments, hospitalization costs, funeral and burial expenses and the mental anguish suffered by her surviving family members.

    Xarelto Internal Bleeding Complications

    Approved by the FDA in 2011, Xarelto quickly became a popular blood clot treatment for atrial fibrillation patients and was commonly prescribed to patients after hip or knee surgery. Xarelto manufacturers promoted the medication through a direct-to-consumer advertising designed to encourage patients to ask their doctors about being prescribed the anticoagulant.

    The ad campaign seemed to work as Xarelto manufacturers tout that the medication is now the top blood thinner in its class with its 11 million prescriptions in the U.S. alone.

    However, it only took a few months of being on the market when the FDA began receiving adverse reports from consumers claiming Xarelto caused serious internal bleeding complications.

    In the years since its release, Xarelto has been named in thousands of adverse reports, hundreds of those claiming the drug caused a hemorrhage-related death.

    Xarelto Side Effects

    Xarelto was initially promoted as a more convenient blood thinner when compared to Warfarin (Coumadin), as manufacturers assured consumers that the medication required no regular blood testing or carried any dietary restrictions. However, most Xarelto patients fling lawsuits claim they were unaware that there was no antidote should a bleeding event occur.

    Coumadin patients can be given a dose of vitamin k to get bleeding under control, but Xarelto consumers are forced to undergo multiple blood transfusions and lengthy hospital stays as the only known way to stop the internal bleeding is to get the drug out of the system.

    According to recent studies, Xarelto consumers have double the risk of experiencing gastrointestinal bleeding when compared to Warfarin users.

    The Xarelto Bleeding MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:15-cv-03396-EEF-MBN in MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.

    http://topclassactions.com/lawsuit-settlements/lawsuit-news/99805-xarelto-bleeding-lawsuit-joins-mdl-alleging-wrongful-death/
    

    Return to headline | Return to top